Gordon Research Conferences
Meeting Details
Search:
  GO

Personalized Medicine
Gordon Research Conference

Realizing Personalized Medicine Through Integrative Medicine, Science and Technology

Dates

July 10-15, 2016

Location

The Hong Kong University of Science and Technology
Hong Kong, China

Organizers

Chairs:
Chih-Ming Ho & Edward McCabe

Vice Chairs:
Yen Yun & Edward J. Benz

Hong Kong Advisory Board:
Tony F. Chan, Kathryn Song Eng Cheah, Fanny M.C. Cheung, Arthur B. Ellis, Barry Halliwell, Nancy Ip, Jian Lu, Peter Mathieson, Alfonso Ngan, Paul Tam, Benjamin Wah, Henry Wong, Vivian Wing-Wah Yam, Kenneth Young & Albert Cheung-Hoi Yu More Information

Meeting Description

Patient response rates to chemotherapy are fairly low in cancer treatment, often due to human diversity and cancer heterogeneity. For almost all other diseases, the current population-averaged therapeutic approach is also hampered by the human diversity. Therefore, personalized medicine is necessary to improve treatment efficacy/response rate as well as safety by providing precisely tailored patient therapy. In this first GRC on "Personalized Medicine", we will review what we have achieved and how we should move forward.

Combinatorial treatment comprised of drugs, immunotherapy and radiations are commonly used in treating cancer, infectious disease and many other types of diseases for improving therapeutic outcomes and reduced drug resistance. Current methods are far from optimal. In addition, these combinatorial treatments will also vary from patient to patient.

Recent technology developments have enabled the precise determination of which medicines may be most effective for a group of patients with similar gene profiles. Guided by the patient's sequence database, the genotypic precision medicine (GPM) method can locate better targets for discovering new drugs and achieve much higher efficacy to improve response rates.

The major challenges of continually evolving set of genetic and epigenetic factors can render drug resistance. Based on the measured end-point phenotype of a specific patient, the emergence of phenotypic personalized medicine (PPM) can realize unprecedented levels of adaptability to the dynamic patient physical response and rapidly home in the optimized combinatorial therapy for individual personal level.

Current nano/micro technologies enable single cell sequencing, circulating tumor cell analysis, and ultrasensitive diagnosis. By converging GPM, PPM and nano/micro technologies, rationally designed optimal combinatorial therapy for a specific patient through integrative medicine, science and technology will be the next paradigm for personalized medicine.

Contributors

Final Meeting Program

Sunday
2:00 pm - 8:00 pmArrival and Check-in
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pmGenotypic Precision Medicine and Phenotypic Personalized Medicine
Discussion Leader: Bill Gahl (National Human Genome Research Institute, NIH, USA)
7:40 pm - 7:55 pmIntroduction by Discussion Leader
7:55 pm - 8:35 pmBruce Gelb (Icahn School of Medicine at Mount Sinai, USA)
"Getting Personal: The Path from Congenital Heart Disease Genetics to Better Outcomes"
8:35 pm - 8:45 pmDiscussion
8:45 pm - 9:25 pmWee Joo Chng (Cancer Science Institute of Singapore, National University of Singapore, Singapore) and Edward Kai-Hua Chow (Cancer Science Institute of Singapore, National University of Singapore, Singapore)
"Phenotypic Personalized Medicine in Multiple Myeloma"
9:25 pm - 9:30 pmDiscussion
Monday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmPersonalized/Precision Medicine and Enabling Technologies
Discussion Leader: Megan Frisk (Science Translational Medicine, USA)
9:00 am - 9:15 amIntroduction by Discussion Leader
9:15 am - 9:55 amSteven Rosen (City of Hope National Medical Center, USA)
"RNA Directed Therapy (8 Chloro-Adenosine), DNA Directed Therapy (Leflunomide) and Targeting Glucose Metabolism (Ritonavir Plus Metformin) – Bench to Bedside for AML and Myeloma"
9:55 am - 10:10 amDiscussion
10:10 am - 10:40 amGroup Photo / Coffee Break
10:40 am - 11:20 amDean Ho (Weintraub Center for Reconstructive Biotechnology, University of California, Los Angeles, USA)
"Phenotypic Personalized Medicine: Actionable Individualization of Patient Therapy"
11:20 am - 11:35 amDiscussion
11:35 am - 12:15 pmGeoffrey Ginsburg (Duke Center for Applied Genomics and Precision Medicine, USA)
"Novel Paradigms for the Early Detection of Acute and Chronic Disease"
12:15 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
3:00 pm - 4:00 pmPower Hour
The GRC Power Hour is an optional informal gathering open to all meeting participants. It is designed to help address the challenges women face in science and support the professional growth of women in our communities by providing an open forum for discussion and mentoring.
Organizer: Megan Frisk (Science Translational Medicine, USA)
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmPersonalized Pediatric Medicine
Discussion Leader: Katherine Janeway (Dana-Farber Cancer Institute, Harvard University, USA)
7:30 pm - 7:45 pmIntroduction by Discussion Leader
7:45 pm - 8:25 pmDennis Lo (Chinese University of Hong Kong, Hong Kong SAR China)
"Unlocking Hidden Diagnostic Information from Plasma DNA"
8:25 pm - 8:40 pmDiscussion
8:40 pm - 9:20 pmCharles Roberts (St. Jude Children's Research Hospital, USA)
"SWI/SNF (BAF) Complex Mutations in Cancer: Mechanisms and Therapeutic Vulnerabilities"
9:20 pm - 9:30 pmDiscussion
Tuesday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmIntersection of Engineering and Medicine
Discussion Leader: Hsing Jien Kung (National Health Research Institutes, Taiwan)
9:00 am - 9:15 amIntroduction by Discussion Leader
9:15 am - 10:00 amYanyi Huang (Peking University, China)
"Connection Between the Heterogeneous Phenotypes and Genotypes at Single-Cell Level"
10:00 am - 10:15 amDiscussion
10:15 am - 10:30 amCoffee Break
10:30 am - 11:15 amGarry Nolan (Stanford University, USA)
"Single Cell Deep Profiling of Cancer and Immunity"
11:15 am - 11:30 amDiscussion
11:30 am - 12:15 pmPasi Janne (Dana-Farber Cancer Institute, USA)
"Strategies to Overcome Drug Resistance in EGFR Mutant Lung Cancer"
12:15 pm - 12:30 pmDiscussion
12:30 pmLunch
2:00 pm - 4:00 pmPoster Session
4:00 pm - 6:00 pmIndividualized Medicine for Cancers
Discussion Leader: Richard Weinshilboum (Mayo Medical School, Mayo Clinic, USA)
4:00 pm - 4:15 pmIntroduction by Discussion Leader
4:15 pm - 4:55 pmXianting Ding (Institute for Personalized Medicine, Shanghai Jiao Tong University, China)
"In Vivo Drug Combination Optimization for Colon Cancer Treatment Through a Phenotype Personalized Medicine (PPM) Approach"
4:55 pm - 5:10 pmDiscussion
5:10 pm - 5:50 pmArjan Griffioen (VU University Medical Center, The Netherlands) and Patrycja Nowak-Sliwinska (University of Geneva, Switzerland)
"Identification of Optimal Personalized Combination Therapy for Renal Cell Cancer"
5:50 pm - 6:00 pmDiscussion
6:00 pmDinner
Wednesday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmGenomics and Molecular Targets
Discussion Leader: Garry Cutting (Johns Hopkins University, USA)
9:00 am - 9:15 amIntroduction by Discussion Leader
9:15 am - 9:55 amPan-Chyr Yang (National Taiwan University, Taiwan)
"Precision Lung Cancer Therapy: EGFR-TK1 and Beyond"
9:55 am - 10:10 amDiscussion
10:10 am - 10:40 amCoffee Break
10:40 am - 11:20 amC. Thomas Caskey (Baylor College of Medicine, USA)
"Metabolomics Adds Function to Genetic Precision Medicine"
11:20 am - 11:35 amDiscussion
11:35 am - 12:15 pmWilliam Mobley (University of California, San Diego, USA)
"Defining Genes and Mechanisms Underlying Cognitive Deficits in Down Syndrome"
12:15 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:00 pm - 7:30 pmBusiness Meeting
Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
7:30 pm - 9:30 pmPersonalized Therapies for Blood Disorders
Discussion Leader: Qiang Tian (P4 Medicine Institute, USA)
7:30 pm - 7:45 pmIntroduction by Discussion Leader
7:45 pm - 8:25 pmAndrew Feldman (Mayo Clinic Cancer Center, USA)
"Individualizing Therapy in Lymphoma"
8:25 pm - 8:40 pmDiscussion
8:40 pm - 9:20 pmKarl Tsim (Hong Kong University of Science and Technology, Hong Kong SAR China) and Yi-Kuen Lee (Hong Kong University of Science and Technology, Hong Kong SAR China)
"Traditional Chinese Medicine: A Yin-Yang Balance of Personalized Medicine"
9:20 pm - 9:30 pmDiscussion
Thursday
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmPersonalized Immunotherapy
Discussion Leader: Patrick Tan (Duke-NUS Medical School, Singapore)
9:00 am - 9:15 amIntroduction by Discussion Leader
9:15 am - 10:00 amYusuke Nakumura (Center for Personalized Therapeutics, University of Chicago, USA)
"Cancer Precision Medicine and Neoantigen Vaccine Treatment"
10:00 am - 10:15 amDiscussion
10:15 am - 10:30 amCoffee Break
10:30 am - 11:15 amLieping Chen (Yale University, USA)
"The PD-1/PD-L1 Blockade: A New Class of Cancer Immunotherapy"
11:15 am - 11:30 amDiscussion
11:30 am - 12:15 pmAli Zarrinpar (David Geffen School of Medicine at UCLA, USA)
"Patient-Specific Drug Interaction Mapping in Personalized Immunosuppression"
12:15 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmLate-Breaking Topics
Discussion Leader: Yiwu He (BGI, China)
4:00 pm - 4:20 pmIntroduction by Discussion Leader
4:20 pm - 4:50 pmGunaretnam Rajagopal (Janssen R&D, USA) and Zhen Gu (University of North Carolina at Chapel Hill, USA)
"Integration of GPM. PPM and Enabling Technologies"
4:50 pm - 5:00 pmDiscussion
5:00 pm - 5:30 pmNavaline Quach (Tecan, USA) and Julia Zhen (Thermo Fisher Scientific, USA)
"Industrial Participation and Government Regulatory Process"
5:30 pm - 5:40 pmDiscussion
5:40 pm - 6:00 pmGeneral Discussion
6:00 pmDinner
Friday
7:30 am - 8:30 amBreakfast
9:00 amDeparture

Any opinions, findings, conclusions or recommendations expressed in this material/event (or by members of the project team) do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Innovation and Technology Commission or the Vetting Committee of the General Support Programme of the Innovation and Technology Fund.
© 2017 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter